UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000032221
Receipt number R000036743
Scientific Title A study on the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction
Date of disclosure of the study information 2018/04/17
Last modified on 2020/10/13 10:33:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study on the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction

Acronym

A study on the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction

Scientific Title

A study on the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction

Scientific Title:Acronym

A study on the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction

Region

Japan


Condition

Condition

The patients with cancer located at the upper third of the stomach or at around the esophagogastric junction who underwent various types of gastrectomy

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction.

Basic objectives2

Others

Basic objectives -Others

To study the effect of various surgical procedures and clinical factors on postoperative QOL in each type of gastrectomy.

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

The main outcome measures of PGSAS-45 and change in body weight are compared among the different type of gastrectomy for the cancer located at the upper third of the stomach or at the around the esophagogastric junction.

Key secondary outcomes

The effects of the surgical procedures and the clinical factors on postoperative QOL are studied in each type of gastrectomy.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) The patients with cancer located at the upper third of the stomach or at around the esophagogastric junction (with any stage or histologic type).
(2) Achieved R0 resection.
(3) Without any recurrence or metastasis.
(4) The patients who were more than 6 months after gastrectomy.
(5) Allowable of former chemotherapy if more than 6 months past after the termination of the treatment.
(6) The patients who underwent gastrectomy only once.
(7) Performance status 0 or 1.
(8) Capable to understand the questionnaire.
(9) Without any other disease or previous surgery which may influence the results of questionnaire more than gastrectomy.
(10) Without any organ failure or mental disease.
(11) Spontaneous agreement of the said person.

Key exclusion criteria

(1) Active dual malignancy.
(2) Synchronous another surgery with exception of the resection or the extraction of the perigastric organs to accomplish gastrectomy or lymph node dissection, and ones equivalent to cholecystectomy.
(3) Judged as irrelevant by the responsible doctor of this study.

Target sample size

4000


Research contact person

Name of lead principal investigator

1st name Koji
Middle name
Last name Nakada

Organization

The Jikei University Daisan Hospital

Division name

Department of Laboratory Medicine

Zip code

201-8601

Address

4-11-1, Izumihoncyo, Komae-shi, Tokyo, 201-8601 Japan

TEL

03-3480-1151

Email

nakada@jikei.ac.jp


Public contact

Name of contact person

1st name Koji
Middle name
Last name Nakada

Organization

The Jikei University Daisan Hospital

Division name

Department of Laboratory Medicine

Zip code

201-8601

Address

4-11-1, Izumihoncyo, Komae-shi, Tokyo, 201-8601 Japan

TEL

03-3480-1151

Homepage URL


Email

nakada@jikei.ac.jp


Sponsor or person

Institute

Japan Postgastrectomy Syndrome Working Party
Japanese Society for Gastro-surgical Pathophysiology

Institute

Department

Personal name



Funding Source

Organization

Self-funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee, The Jikei University School of Medicine

Address

3-25-8,Nishishimbashi, Minato-ku, Tokyo, 105-8461 Japan

Tel

03-3433-1111

Email

rinri@jikei.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京慈恵会医科大学附属第三病院(東京都)、佐久市立国保浅間総合病院(長野県)、横浜市立市民病院消化器外科(神奈川県)、金沢医科大学(石川県)、国際医療福祉大学病院(栃木県)、今村総合病院(鹿児島県)、名古屋大学(愛知県)、東京大学(東京都)、横浜市立大学附属市民総合医療センター(神奈川県)、岐阜大学(岐阜県)、四国がんセンター(愛媛県)、新潟県立がんセンター新潟病院(新潟県)、がん研有明病院(東京都)、県立広島病院(広島県)、東京慈恵会医科大学附属病院(東京都)、 公立みつぎ総合病院(広島県)、順天堂大学(東京都)、函館五稜郭病院(北海道)、静岡県立静岡がんセンター(静岡県)、滋賀医科大学(滋賀県)、山形県立中央病院(山形県)、島根大学(島根県)、千葉県がんセンター(千葉県)、獨協医科大学(栃木県)、東邦大学医療センター大橋病院(東京都)、愛知県がんセンター中央病院(愛知県)、済生会川内病院(鹿児島県)、大阪医科大学(大阪府)、城山病院(大阪府)、京都府立医科大学(京都府)、大阪府済生会野江病院(大阪府)、堺市立総合医療センター(大阪府)、山梨大学(山梨県)、高知大学(高知県)、札幌医科大学(北海道)、鹿児島大学(鹿児島県)、大阪市立大学(大阪府)、勤医協中央病院(北海道)、呉医療センター・中国がんセンター(広島県)、東京医科大学(東京都)、おおもと病院(岡山県)、帝京大学(東京都)、箕面市立病院(大阪府)、前橋赤十字病院(群馬県)、石川県立中央病院(石川県)、南大阪病院(大阪府)、聖路加国際病院(東京都)、日赤和歌山医療センター(和歌山県)、大分県厚生連鶴見病院(大分県)、富山県立中央病院(富山県)、奈良県立医科大学(奈良県)、JA広島総合病院(広島県)、青森県立中央病院(青森県)、聖マリアンナ医科大学(神奈川県)、山口大学(山口県)、千葉大学(千葉県)、広島市立安佐市民病院(広島県)、 国立がん研究センター中央病院(東京都)、久留米大学(福岡県)、京都医療センター(京都府)、岐阜市民病院(岐阜県)、立川メディカルセンター(東京都)、北海道消化器科病院(北海道)、秋田厚生医療センター(秋田県)、大分大学(大分県)、鳥取大学(鳥取県)、名古屋市立大学(愛知県)、北野病院(大阪府)、大津市民病院(滋賀県)、京都大学(京都府)、広島市立広島市民病院(広島県)、広島大学(広島県)、熊本大学(熊本県)、岩手医科大学(岩手県)、栃木県立がんセンター(栃木県)、神戸大学(兵庫県)、仙台医療センター(宮城県)、長岡中央綜合病院(新潟県)、鈴鹿中央総合病院(三重県)、関西医科大学附属病院(大阪府)、宮城県立がんセンター(宮城県)、埼玉医科大学総合医療センター(埼玉県)、福山市民病院(広島県)、東海大学医学部付属八王子病院(東京都)、りんくう総合医療センター(大阪府)、九州大学(福岡県)、筑波大学(茨城県)、八尾市立病院(大阪府)、神奈川県立がんセンター(神奈川県)、関西労災病院(兵庫県)、弘前大学(青森県)、昭和大学藤が丘病院(神奈川県)、東海大学(神奈川県)、鳥取県立中央病院(鳥取県)、佐世保市総合医療センター(長崎県)、慶應義塾大学(東京都)、大阪急性期・総合医療センター(大阪府)、広島記念病院外科(広島県)、生麦病院(神奈川県)、佐久医療センター(長野県)、JCHO札幌北辰病院(北海道)、福岡大学病院(福岡県)、埼玉医科大学国際医療センター(埼玉県)、北里大学北里研究所病院(東京都)


Other administrative information

Date of disclosure of the study information

2018 Year 04 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

1909

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 03 Month 17 Day

Date of IRB

2018 Year 04 Month 10 Day

Anticipated trial start date

2018 Year 07 Month 01 Day

Last follow-up date

2020 Year 01 Month 31 Day

Date of closure to data entry

2020 Year 04 Month 17 Day

Date trial data considered complete

2020 Year 05 Month 17 Day

Date analysis concluded

2020 Year 10 Month 17 Day


Other

Other related information

(1) Date of birth, gastrectomy and entry in the questionnaire
(2) Sex
(3) Height, body weight (at just before gastrectomy and at entry in the questionnaire)
(4) Pathological stage, histological type, location of the cancer
(5) Presence or absence of either neoadjuvant or adjuvant chemotherapy, regimens
(6) The level of esophago-gastric or esophago-jejunal anastomosis
(7) Type of gastrectomy and reconstruction method
And so on


Management information

Registered date

2018 Year 04 Month 12 Day

Last modified on

2020 Year 10 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036743


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name